Latest News Archive

Please select Category, Year, and then Month to display items

Health Sciences awards first Bongani Mayosi Medical Students Academic Prize

12 December 2020 | Story André Damons

Bongani Mayosi Prize Latest News — Drs Kaamilah Joosub (in front) and Lynette Upman, medical students in the Faculty of Health Sciences at the UFS, are the winners of the first Bongani Mayosi Medical Students Academic Prize for final-year medical students.

Two final-year medical students from the University of the Free State (UFS) became the first recipients of the prestigious Bongani Mayosi Medical Students Academic Prize which was bestowed on them 10 days before their graduation.

Drs Kaamilah Joosub and Lynette Upman, two final-year medical students in the Faculty of Health Sciences at the UFS are the first medical students from the university to be awarded the prize.This is the first year it has been awarded.

Drs Joosub and Upman received their awards at a function on Friday (4 December 2020) from Prof Hanneke Brits, Phase III chair and specialist in the Department of Family Medicine, on behalf of Prof Gert van Zyl, Dean of the Faculty of Health Sciences.

The Faculty of Health Sciences will host a virtual graduation on 14 December 2020.

Prestigious national award

The Bongani Mayosi Medical Students Academic Prize is a prestigious national award which aims to recognise final-year medical students who epitomise the academic, legendary, and altruistic life of Mayosi. The awards are presented to final-year MB ChB students from all South African medical faculties. Each student is allowed one vote for one classmate who, in their private opinion, best balances:

Academic achievement
Emotional intelligence ‑ good interpersonal skills
Social accountability ‑ the ability to respond helpfully to the needs of others

Winners are determined by the highest number of digital votes, with the first-prize winner receiving R6 000 and second prize coming in at R4 000.

Dr Lynette van der Merwe, undergraduate medical programme director in the School of Clinical Medicine at UFS, commented that Drs Joosub and Upman are worthy winners, as they have continuously exemplified the ideals recognised by this award during their undergraduate training.

The School of Clinical Medicine is very proud of its newest Kovsie doctors who successfully completed the academic year despite the immense challenges associated with the COVID-19 pandemic. This is thanks to the commitment and hard work of students and staff at the UFS.

Name behind the prize

The late Prof Bongani Mayosi was an outstanding doctor who rose rapidly through the ranks to become a top cardiologist, internationally recognised as a leading clinician scientist. He completed his undergraduate studies at the age of 22, having graduated cum laude in both the Bachelor of Medicine and Surgery (MB ChB) and Bachelor of Medical Sciences (BMedSci) degrees.

He trained as a physician and cardiologist at Groote Schuur Hospital and completed his doctorate at the University of Oxford in the UK. At the age of 38‚ he became the first black to be appointed professor and Head of the Department of Medicine at the University of Cape Town (UCT). In 2016, he was appointed Dean of the Faculty of Health Sciences at UCT. Before taking up his deanship, he completed the Advanced Management Programme at Harvard University in the US.

As a medical student Prof Mayosi excelled academically, was supportive of his classmates and enthusiastically involved in student residence committees and politics as well as community outreach programmes. As a researcher, he initiated an international programme of research focusing on solutions for poverty-related heart diseases and trained local clinician scientists and research leaders.

Prof Mayosi had an exceptional mixture of academic brilliance and vision; ambition and humility; kindness and generosity; passion and compassion; drive and empathy that complemented his ability to persuade and inspire others, which no doubt contributed to his 400 publications.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept